Lupus
The RheumNow faculty reporters have been scouring the meeting and online presentations to find the best abstracts from ACR22. Here are some of their choice abstracts reported today on day 1 of ACR 2022 (#ACRbest).
sheila RHEUMarampa
3 years 11 months ago
P hoc analysis by Dr AGomez et al fr 4 Ph3 RCTs of BEL in #lupus investigated predictors of renal flares
šAdjusted:ā¬ļøc3, plasma alb & proteinuria levels at BL
šNon-adj: antidsDNA+, antiSm+ addt'l predictors
š§p alb & antiSm+ potential predictors?
#ACR22 @RheumNow ABST#540 https://t.co/EYcD7pDYQe
Is patient-administered cervical cancer screening an option for women with SLE? Should I prescribe estrogen containing contraceptives to SLE women with APL antibodies? What complications should I be aware of in pregnant women with SLE? Here are three abstracts that provide insight.
In abstract #0327 presented during the poster session on Saturday, Dr. Ai Li Yeo and colleagues investigated the usefulness of serial anti-dsDNA testing in predicting flares among SLE patients who have persistently positive anti-dsDNA titers.
Mike Putman EBRheum
3 years 11 months ago
Nice #SLE validation study. This kind of work is (1) time intensive and (2) thankless!
It's not flashy but it winds up being the backbone/foundation for many subsequent studies
Need more in other diseases, including sarcoidosis and myositis! @DidemSayginMD
#ACR22 @RheumNow https://t.co/64z7DBFCnX
Eric Dein ericdeinmd
3 years 11 months ago
Ab0349 #ACR22 BEL vs AZA ifn risks in non-renal SLE
BEL: lower risk of severe ifn (HR 0.81) and hospitalization for ifn (HR 0.73) through 5 yrs
Challenge to interpret data as 56% of patients were on glucocorticoids and other anti-rheumatic meds
@RheumNow https://t.co/a0tNFn5Wqr
Recently the FDA approved deucravacitinib, a highly selective TYK2 inhibitor for psoriasis. Trials are positive in psoriatic arthritis and a phase II study in SLE. What about the effects? Presentations from the ACR22 meeting may provide answers.
Janet Pope Janetbirdope
3 years 11 months ago
Is it the medication or behaviour that increases mortality? #SLICC grp showed in #SLE severe non-adherence to #HCQ in Yr 1 of #lupus = 3 poor outcomes -more 1 flares, 2 damage, 3 5yr-death. Surrogate of other poor health behaviours and/or HCQ? abst#0343 #ACR22 #ACRBest @RheumNow https://t.co/tTRdyti0sf
Eric Dein ericdeinmd
3 years 11 months ago
Ab#0348 #ACR22: Meta-analysis of Belimumab for CLE w or w/o SLE
13 studies included: 70% with low risk of bias
BEL improved clinical response at W52 vs non-users OR 1.44
Decrease risk of severe cutaneous flare OR 0.51
Most studies against placebo group
@RheumNow https://t.co/2bSwNKRHZZ
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 11 months ago
#ACR22 Year in Review. Dr Varga highlighted work by @Kahlenberglab. Non-lesional skin in patients with #lupus is not normal and is IFN-riched. Also implication for future therapy development to target organ/tissues vs circulation @RheumNow https://t.co/rSnLYrZoMO
Eric Dein ericdeinmd
3 years 11 months ago
Ab0343. #ACR22 Severe non-adherence of HCQ associated with FLARES, DAMAGE and DEATH
7.3% had "severe non-adherence" by HCQ levels
Hazard ratio of flare 3.3, damage 4.26, and death 5.4
Not surprising, but very useful for pt discussion
Checking HCQ levels are helpful!
@Rheumnow https://t.co/S7P9oTPRGJ
TheDaoIndex KDAO2011
3 years 11 months ago
Dr. C Langford's pick for #YearinReview; she is impressed with the novel mechanistic approaches to #SLE @rheumnow #ACR22. https://t.co/5GrtMYYZSv
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 11 months ago
#ACR2022 Year in Review. Dr Varga highlighted work by @GeorgeTsokos. In #lupus mice, adding CD38-i in a CD8+ T cellātargeted manner improved effector function, reversed the defects and improved viral clearance. CD38 as a target could reduce infection in SLE @rheumnow https://t.co/XlmvysjkDP
